(Sharecast News) - Pharmaceutical company GlaxoSmithKline announced it will produce 1bn doses of coronavirus vaccine booster in preparation for an eventual immunisation drive.
GSK said its adjuvant could make "a significant contribution against Covid-19".
The company said it was in talks with governments to back the expansion of its manufacturing capabilities and that production would take place at sites in Europe and North America.
"As demonstrated in the last flu pandemic, GSK's pandemic adjuvant can reduce the amount of vaccine protein required per dose, which allows more vaccine doses to be produced, contributing to protecting more people," GSK said according to the FT. "Additionally, an adjuvant can enhance the immune response and has been shown to create a stronger and longer-lasting immunity against infections."
The pharmaceutical industry is still racing to produce viable vaccine candidates to fight Covid-19.
Roger Connor, president of GSK's global vaccines division, said more than one vaccine would be needed to address the pandemic.
GSK is currently working with Sanofi on a vaccine candidate.
The company's stock was up 1.26% on Thursday, trading at 1,669p.
Glaxosmithkline (GSK)25 Apr 2024 15:53
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
April 25 (Reuters) - GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related...
